Caseware UK (AP4) 2025.0.111 2025.0.111 2026-05-312026-05-3112025-06-01falseMedical services1truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 14085702 2025-06-01 2026-05-31 14085702 2024-06-01 2025-05-31 14085702 2026-05-31 14085702 2025-05-31 14085702 2024-06-01 14085702 c:Director1 2025-06-01 2026-05-31 14085702 d:MotorVehicles 2025-06-01 2026-05-31 14085702 d:MotorVehicles 2026-05-31 14085702 d:MotorVehicles 2025-05-31 14085702 d:MotorVehicles d:OwnedOrFreeholdAssets 2025-06-01 2026-05-31 14085702 d:ComputerEquipment 2025-06-01 2026-05-31 14085702 d:ComputerEquipment 2026-05-31 14085702 d:ComputerEquipment 2025-05-31 14085702 d:ComputerEquipment d:OwnedOrFreeholdAssets 2025-06-01 2026-05-31 14085702 d:OwnedOrFreeholdAssets 2025-06-01 2026-05-31 14085702 d:CurrentFinancialInstruments 2026-05-31 14085702 d:CurrentFinancialInstruments 2025-05-31 14085702 d:CurrentFinancialInstruments d:WithinOneYear 2026-05-31 14085702 d:CurrentFinancialInstruments d:WithinOneYear 2025-05-31 14085702 d:ShareCapital 2025-06-01 2026-05-31 14085702 d:ShareCapital 2026-05-31 14085702 d:ShareCapital 2024-06-01 2025-05-31 14085702 d:ShareCapital 2025-05-31 14085702 d:ShareCapital 2024-06-01 14085702 d:RetainedEarningsAccumulatedLosses 2025-06-01 2026-05-31 14085702 d:RetainedEarningsAccumulatedLosses 2026-05-31 14085702 d:RetainedEarningsAccumulatedLosses 2024-06-01 2025-05-31 14085702 d:RetainedEarningsAccumulatedLosses 2025-05-31 14085702 d:RetainedEarningsAccumulatedLosses 2024-06-01 14085702 c:FRS102 2025-06-01 2026-05-31 14085702 c:AuditExempt-NoAccountantsReport 2025-06-01 2026-05-31 14085702 c:FullAccounts 2025-06-01 2026-05-31 14085702 c:PrivateLimitedCompanyLtd 2025-06-01 2026-05-31 14085702 d:KeyManagementIndividualGroup1 d:OtherTransactionType1 2025-06-01 2026-05-31 14085702 d:KeyManagementIndividualGroup1 d:OtherTransactionType1 2026-05-31 14085702 d:KeyManagementIndividualGroup1 d:OtherTransactionType1 2025-05-31 14085702 2 2025-06-01 2026-05-31 14085702 e:PoundSterling 2025-06-01 2026-05-31 iso4217:GBP xbrli:pure

Registered number: 14085702










DALES DOCTORS LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MAY 2026

 
DALES DOCTORS LIMITED
REGISTERED NUMBER: 14085702

BALANCE SHEET
AS AT 31 MAY 2026

2026
2025
Note
£
£

Fixed assets
  

Tangible fixed assets
  
435
37,902

  
435
37,902

Current assets
  

Debtors: amounts falling due within one year
 5 
1,495
11,419

Bank and cash balances
  
73,237
88,212

  
74,732
99,631

Creditors: amounts falling due within one year
 6 
(18,235)
(22,893)

Net current assets
  
 
 
56,497
 
 
76,738

Total assets less current liabilities
  
56,932
114,640

Provisions for liabilities
  

Deferred tax
  
(109)
(9,476)

  
 
 
(109)
 
 
(9,476)

Net assets
  
56,823
105,164


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
56,723
105,064

  
56,823
105,164


Page 1

 
DALES DOCTORS LIMITED
REGISTERED NUMBER: 14085702
    
BALANCE SHEET (CONTINUED)
AS AT 31 MAY 2026

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
J P Smith
Director

Date: 7 September 2026

The notes on pages 5 to 10 form part of these financial statements.

Page 2

 
DALES DOCTORS LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MAY 2026


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 June 2025
100
105,064
105,164


Comprehensive income for the year

Profit for the year

-
29,659
29,659


Other comprehensive income for the year
-
-
-


Total comprehensive income for the year
-
29,659
29,659


Contributions by and distributions to owners

Dividends: Equity capital
-
(78,000)
(78,000)


Total transactions with owners
-
(78,000)
(78,000)


At 31 May 2026
100
56,723
56,823


The notes on pages 5 to 10 form part of these financial statements.

Page 3

 
DALES DOCTORS LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MAY 2025


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 June 2024
100
98,500
98,600


Comprehensive income for the year

Profit for the year

-
57,614
57,614


Other comprehensive income for the year
-
-
-


Total comprehensive income for the year
-
57,614
57,614


Contributions by and distributions to owners

Dividends: Equity capital
-
(51,050)
(51,050)


Total transactions with owners
-
(51,050)
(51,050)


At 31 May 2025
100
105,064
105,164


The notes on pages 5 to 10 form part of these financial statements.

Page 4

 
DALES DOCTORS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2026

1.


General information

Dales Doctors Limited is a private company limited by shares incorporated in England and Wales. The 
registered office is Wingate House, Bent Lane, Darley Dale, Matlock, DE4 2HN. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in the Profit and Loss Account using the effective interest method.

Page 5

 
DALES DOCTORS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2026

2.Accounting policies (continued)

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
25%
straight line per annum
Computer equipment
-
33%
straight line per annum

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Profit and Loss Account.

Page 6

 
DALES DOCTORS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2026

2.Accounting policies (continued)

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to the Profit and Loss Account.

Page 7

 
DALES DOCTORS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2026

2.Accounting policies (continued)

  
2.10

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at transaction price, net of transaction costs, and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit and Loss Account.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the Balance Sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 
2.11

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 8

 
DALES DOCTORS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2026

3.


Employees

The average monthly number of employees, including the director, during the year was as follows:


        2026
        2025
            No.
            No.







Total
1
1


4.


Tangible fixed assets


Motor vehicles
Computer equipment
Total

£
£
£



Cost or valuation


At 1 June 2025
69,548
1,183
70,731


Additions
-
349
349


Disposals
(69,548)
-
(69,548)



At 31 May 2026

-
1,532
1,532



Depreciation


At 1 June 2025
31,876
953
32,829


Charge for the year
14,489
144
14,633


Disposals
(46,365)
-
(46,365)



At 31 May 2026

-
1,097
1,097



Net book value



At 31 May 2026
-
435
435



At 31 May 2025
37,672
230
37,902


5.


Debtors

2026
2025
£
£


Trade debtors
1,495
11,419

1,495
11,419


Page 9

 
DALES DOCTORS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2026

6.


Creditors: Amounts falling due within one year

2026
2025
£
£

Corporation tax
15,625
20,655

Other creditors
816
535

Accruals and deferred income
1,794
1,703

18,235
22,893



7.


Transactions with directors

At the start of the period, the company owed the director £535. During the period, the director received advances of £799 and made repayments of £1,080 leaving a balance of £816 owed by the company at the period end. No interest was charged during the period.

 
Page 10